Retatrutide is an experimental triple agonist from Eli Lilly. Here's what the phase 2 data show, where phase 3 stands, and what to watch for.

Retatrutide is one of the most talked-about drugs in obesity research right now, and it's easy to see why. Early trial numbers for this experimental injectable looked higher than what most people have seen from earlier medicines. But retatrutide is still under study, and as far as we know at the time of writing, it isn't approved for weight loss anywhere. Here's what it is, where it stands, and how to read the headlines.

What retatrutide is and how it differs from tirzepatide

Retatrutide (also coded LY3437943) is an investigational injectable made by Eli Lilly. Its defining feature is that it acts on three hormone receptors instead of two. It's called a “triple agonist” because it switches on GIP, GLP-1, and glucagon receptors at the same time. An agonist is simply a molecule that activates a receptor, a bit like a key turning a lock.

Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight management in the US, targets only two of these: GIP and GLP-1. Retatrutide adds glucagon to the mix.

Each receptor does something different. GLP-1 activation slows stomach emptying and signals fullness to the brain, which tends to reduce appetite. GIP plays a role in insulin release after meals and also seems to influence how the body handles fat. Glucagon is often linked to raising blood sugar, but it may also increase energy expenditure and affects how the liver processes fat. Researchers are still working out how much each piece contributes to the final result.

If you already know tirzepatide, retatrutide is the obvious next comparison. TirzeBlog covers tirzepatide in plain language, so it's a good place to get up to speed on the older drug first.

On approval status, the difference is clear. Tirzepatide is approved: Mounjaro received FDA approval for type 2 diabetes in 2022, and Zepbound was approved for chronic weight management in late 2023. Retatrutide has no approval from the FDA or the European Medicines Agency at the time of writing. Check both agencies' websites before relying on this, since regulatory status can change quickly.

The phase 2 results that put it on the map

The study that drew wide attention was a phase 2 obesity trial published in the New England Journal of Medicine in 2023, led by Ania Jastreboff and colleagues. Participants with obesity received weekly injections of retatrutide or placebo for 48 weeks. At the highest dose, the average weight loss reported in the paper's abstract was about 24% of body weight, compared with a small loss in the placebo group.

Weight loss increased with dose. Higher doses produced larger average reductions, which is a pattern seen across this drug class. The trial also reported how many people stopped treatment because of adverse events, and those rates were higher at the upper doses. The paper's tables give the exact figures, so read them directly instead of relying on summaries.

Separate phase 2 studies looked at type 2 diabetes and liver fat. The diabetes work was published in The Lancet in 2023. Liver fat reductions were also reported and were connected to the glucagon component, a finding researchers want to confirm in larger studies. Check each publication's details before citing its numbers.

Phase 2 results deserve caution. These trials enroll relatively small groups, run for a limited time, and use selected participants under close supervision. They show early signals about effect and safety across a range of doses. They don't establish final efficacy, and they can't reveal long-term effects.

Where the research stands now

Eli Lilly calls its late-stage program TRIUMPH. Based on the company's public descriptions, the program includes studies in adults with obesity, in people with obesity and knee osteoarthritis, and in people with obesity who also have type 2 diabetes or cardiovascular disease. A separate diabetes program, TRANSCEND-T2D, studies the drug in people with type 2 diabetes. Lilly has also described outcome studies that look at heart and kidney health. Confirm official titles, enrollment status, and enrollment numbers on ClinicalTrials.gov.

Drug development moves through phases. Phase 1 studies look mainly at safety and dosing in a small number of people. Phase 2 studies test whether the drug works and which doses make sense. Phase 3 studies are larger and longer, and they confirm benefit while watching for side effects in many more people. A regulatory submission generally requires phase 3 results, and regulators review those results before deciding anything.

Here's the current picture. Lilly has begun announcing topline results from some TRIUMPH and related studies, while others are still enrolling or following participants. Because this changes often, pull the latest status from Lilly's investor newsroom and from ClinicalTrials.gov, where each study lists its current state. Our coverage here on TirzeBlog will be updated as major readouts arrive.

No approval timeline is known. Anyone naming a specific launch date is guessing.

Side effects and safety questions researchers are tracking

Gastrointestinal effects are the most common side effects of incretin-based drugs. Nausea, diarrhea, constipation, and vomiting were reported in the phase 2 obesity trial, and they tend to appear or worsen as doses increase. The NEJM paper breaks these rates down by dose, so check its safety tables for specifics.

Dysesthesia is a sensation like tingling, prickling, or numbness on the skin, and it drew attention because it isn't a typical GLP-1 side effect. It was reported in the phase 2 obesity trial, and it appeared more often at higher doses. Researchers want to know how often it happens, how long it lasts, and whether it resolves on its own. Verify the exact frequencies in the publication before drawing conclusions.

Some reports also described increases in heart rate linked to the glucagon component. The pattern appeared to be dose-related in the phase 2 data. Look up the exact figures in the source papers, since numbers from summaries can be imprecise.

Long-term safety matters most here. Phase 2 studies last only about a year, and rare events or late-appearing problems often show up only in larger, longer trials. Until phase 3 data mature, nobody can fully judge the balance between benefit and risk.

Why it became news and what the headlines leave out

Three things pushed retatrutide into the spotlight. The first was the 2023 phase 2 publication in the New England Journal of Medicine. The second was the weight loss percentage, which looked large compared with earlier obesity medicines. The third was phase 3 news and announcements from Lilly. Each of these can be traced to a dated journal article or press release, and those sources are the best place to check any claim.

Headline numbers come from specific trial populations. Participants were carefully selected, closely monitored, and often supported with diet and activity guidance. Averages also hide a wide range. Some people lost much more than the reported mean, and some lost much less. A typical person may not experience the same results, so treat any single figure as a trial result, not a promise.

The gray market is a real concern. Some online sellers offer retatrutide or “research peptides” without any prescription or regulatory oversight. The FDA has repeatedly warned consumers about unapproved GLP-1 products. Unknown doses, unverified purity, and questionable sterility can lead to infections, contamination, or dosing errors. Products labeled “for research use only” don't go through clinical review.

You can check claims yourself. Look for the trial registration number, usually an NCT identifier on ClinicalTrials.gov. Then check the journal, the sample size, the length of the study, and the comparator arm. A placebo comparison is different from a comparison with an active drug, and that difference changes how a result should be read. Our TirzeBlog team also recommends checking whether a claim comes from a primary study or a secondary article that repeats it.

What to do if you're interested now

Retatrutide isn't available through legitimate prescription channels for weight loss. Any offer to buy it should be treated as a red flag, especially if it promises fast results or skips a medical evaluation.

If you're already on tirzepatide or considering it, talk with your prescriber about your goals, the current evidence, and how your progress will be monitored. Switching between incretin drugs is a medical decision that depends on your health history, your response so far, and your side effects. Don't switch on your own because of a headline.

Bring specific questions to your appointment:

What clinical trials, if any, are open for my condition?
What monitoring would you use to track my safety and progress?
What are my options if my weight loss stalls?
How would switching medications affect my dose and my side effect risk?

If you want to explore research studies, ClinicalTrials.gov lists trials with their eligibility criteria, locations, and contact details. Eligibility rules are strict, and each study requires informed consent. That consent document explains the procedures, risks, and alternatives, and it makes clear that you can leave a study at any time. Ask questions until everything is clear before you sign.

FAQ

Is retatrutide approved?

No. As of the time of writing, retatrutide has not been approved by the FDA or the European Medicines Agency for any use. Check both agencies' websites for the latest status.

Is retatrutide better than tirzepatide?

It's too early to say. Phase 2 trials showed larger average weight loss in their own designs, but cross-trial comparisons are unreliable. Phase 3 results will give a much clearer answer.

Does retatrutide cause dysesthesia?

Dysesthesia was reported in the phase 2 obesity trial, more often at higher doses. Researchers are still studying how common it is and how long it lasts. Discuss any unusual skin sensations with a doctor.

Can I buy retatrutide online?

There is no legitimate prescription route for retatrutide for weight loss right now. Products sold online as retatrutide or research peptides carry risks of unknown dose, purity, and sterility, so it's best to avoid them.

Sources